# Reviewer role

`figure-narrative-reporting` — independent assessment of figure–text–legend–source closure, internal numerical consistency, article architecture, transparent reporting, and compliance. This review does not adjudicate domain novelty, full statistical validity, or biological mechanism except where the manuscript’s presentation makes a figure-supported claim that the stated comparison cannot establish.

# Material inspected and assessment boundary

- Frozen manuscript: `/tmp/manuscript-skill-benchmark-20260720.zGfMWO/shared/manuscript.md`; SHA-256 `d51224a5ec717a268dadeee2fe9461a7b9d8c833f5b459be2d522a88d5c0006f`.
- Frozen inventory: `/tmp/manuscript-skill-benchmark-20260720.zGfMWO/shared/00_input_inventory.json`.
- Frozen official journal profile: `/tmp/manuscript-skill-benchmark-20260720.zGfMWO/shared/nature-journal-profile.json`; SHA-256 `6f6386d213e195d6ec26d0c177568f27753208425a6a15ce139b1ac2235fd6eb`.
- Frozen shared factual intake: `/tmp/manuscript-skill-benchmark-20260720.zGfMWO/shared/02_shared_fact_base.md`; SHA-256 `947b2ed3c744626d5eadc56845b65f223c6b0d4336bd765e3c714acf4ff4a976`.
- Figure legends were inspected, but figure images, tables, supplementary information, raw data, source code, protocols, and reporting checklists were not supplied. Therefore visual quality, plotted-value accuracy, source-data agreement, and any unprovided table or supplement content are **NOT ASSESSABLE**. Their absence from this packet is not treated as proof that they do not exist in the underlying study.
- No external browsing or replacement journal profile was used.

# Journal standard applied

Target: **Nature**, Article, initial submission. I applied the supplied broad-flagship strictness card and the frozen profile: outstanding scientific importance and an interdisciplinary conclusion (N001); technical soundness, strength of evidence, novelty, field importance, and general-audience interest (N002); reproducible Methods (N006); the specified manuscript sequence and declarations (N007); and the initial-file expectation that text and figures are preferably combined (N008). I also enforced the stated ceiling that observational, retrospective, cell-line, and xenograft evidence cannot by itself establish universal clinical actionability or human treatment benefit.

# Overall assessment

The reporting package is not ready for Nature review in its current form. The manuscript has a directly verifiable three-way conflict in the headline 3-year AUC, presents a data-reused split as “independent” validation, and uses figure narratives to imply T-cell exclusion and anti-PD-1 sensitization without the comparisons described in Methods. The legends are too sparse to make the display items interpretable on their own. Reproducibility and ethics declarations are also incomplete in the supplied manuscript text.

Critical gates:

| Gate | Status | Basis |
|---|---|---|
| Frozen-input identity | PASS | All three supplied hashes match the assignment. |
| Headline number consistency across Abstract, Results, and Figure 3 legend | FAIL | 0.91, 0.84, and 0.86 are all reported for the validation-set 3-year AUC. |
| Figure-claim comparison closure | FAIL | Figure 2 is used for an exclusion claim from an association; Figure 4 is used for anti-PD-1 sensitization although all mice received anti-PD-1 and no untreated comparator is described. |
| Legend interpretability and reporting completeness | FAIL | Legends omit panel-level methods, sample/replicate definitions, statistical encodings, and uncertainty information. |
| Methods/data/code reproducibility | FAIL | Model coefficients, code, analysis data, seeds, and software versions are unavailable or unrecorded in the manuscript. |
| Ethics and animal-reporting declaration | FAIL | Committee/protocol, consent, animal protocol, and humane endpoints are not reported. |
| Visual appearance and figure–source-data reconciliation | NOT ASSESSABLE | Figure images and source data were not supplied. |
| Table and supplement closure | NOT ASSESSABLE | Tables and supplementary information were not supplied. |

# Major strengths

- The four legends map in a logical sequence from single-cell discovery (Figure 1), association (Figure 2), model development (Figure 3), to perturbation experiments (Figure 4).
- The manuscript states several key denominators in the prose: eight single-cell donors, 46,218 retained cells, 72 clinical patients with 31 deaths, two named cell lines, and ten mice with five per group.
- The text candidly identifies important reporting limitations, including the lack of external validation, the full-dataset model selection, absent calibration and decision-curve analyses, one CRISPR guide, no rescue, non-random mouse allocation, lack of blinding, and unavailable data/code components.
- The AUC discrepancy is visible from the supplied text and legend, making it resolvable before any visual assessment.

# BLOCKING issues

## B1. Headline 3-year AUC has three incompatible reported values

- **issue_key:** `auc-3year-three-way-conflict`
- **axis:** `figures-and-tables`
- **severity:** `BLOCKING`
- **Anchor:** Abstract, “AUC of 0.91 for 3-year mortality”; Results, “validation-set 3-year mortality AUC of 0.84”; Figure 3 legend, “Panel C labels the validation AUC as 0.86.”
- **Falsifiable concern:** At least two of these three headline values are incorrect or refer to analyses that are not distinguished. The manuscript additionally states in Results that “3-year outcome status was unavailable for many surviving patients,” yet it does not identify a censoring-aware time-dependent estimator or uncertainty interval. The central performance claim therefore cannot be traced to one defined analysis.
- **Concrete resolution test:** Re-run or retrieve the locked validation analysis; name the 3-year discrimination estimator and censoring method; report the validation denominator, event count, confidence interval, and analysis timestamp/version; reconcile the same verified estimate across Abstract, Results, Figure 3, legend, and source table; if values represent different estimands or versions, label each explicitly and remove the others from the same claim.
- **Journal gate:** **FAIL** — N002 strength-of-evidence gate and figure–text numerical closure.
- **confidence:** `1.00`

## B2. The claimed model cannot be reconstructed from the reported manuscript or availability statement

- **issue_key:** `model-reproduction-package-missing`
- **axis:** `reproducibility`
- **severity:** `BLOCKING`
- **Anchor:** “Score construction and validation,” “Expression cutoffs, coefficient signs, and missing-value rules were also chosen using the full dataset”; “Data and code availability,” “Raw single-cell data, model code, coefficient values, and the final patient-level analysis dataset are not deposited. Random seeds and software versions were not recorded.”
- **Falsifiable concern:** An independent reader cannot calculate the five-gene score, reproduce the split, reconstruct the reported AUC, or verify agreement between the model output and Figure 3 from the information supplied.
- **Concrete resolution test:** Provide the exact five-gene formula with coefficients, transformations, cutoffs, directionality, missing-data rules, and endpoint definition; deposit executable analysis code, environment/software versions, and random seed; provide raw/processed single-cell data and a de-identified or controlled-access patient-level analysis dataset with a documented access route; show that a clean rerun reproduces every reported model value and Figure 3 panel.
- **Journal gate:** **FAIL** — N006 reproducible-Methods requirement and N002 technical-soundness/strength-of-evidence gate.
- **confidence:** `1.00`

## B3. Human and animal oversight information is not reported

- **issue_key:** `ethics-animal-governance-reporting`
- **axis:** `ethical-governance`
- **severity:** `BLOCKING`
- **Anchor:** Ethics, “The approving committee, protocol number, consent procedure, animal protocol, and humane endpoints are not reported.”
- **Falsifiable concern:** The manuscript does not provide enough information to verify prospective human-subject oversight/consent handling or animal-study authorization and humane-endpoint governance.
- **Concrete resolution test:** Add the named human ethics committee, approval identifier, consent procedure or justified waiver, and relevant compliance statement; add the animal oversight body, protocol identifier, species/strain/sex/age as applicable, welfare monitoring, prespecified humane endpoints, and euthanasia criteria; ensure the statements agree with the underlying approvals.
- **Journal gate:** **FAIL** — required declarations/Methods transparency under N007 and technical/ethical reviewability under N002.
- **confidence:** `1.00`

# MAJOR issues

## M1. Figure legends are not sufficiently self-contained to interpret the display items

- **issue_key:** `figure-legends-not-self-contained`
- **axis:** `figures-and-tables`
- **severity:** `MAJOR`
- **Anchor:** Figure legends, “Figure 1. Single-cell workflow and EVA1 expression across tumour-cell clusters”; “Figure 2. Association between EVA1 expression and the T-cell score in eight tumours”; “Figure 3. Development and validation of the five-gene mortality model”; “Figure 4. Cell growth and xenograft volume following EVA1 depletion.”
- **Falsifiable concern:** The supplied legends do not define panels, plotted variables and units, group sizes, biological versus technical replicate units, summary/error displays, statistical tests, exact or thresholded P values, handling of repeated measurements, or the meaning of symbols and abbreviations. A reader cannot determine from the legends what each panel demonstrates or how it was quantified.
- **Concrete resolution test:** For every panel, specify the assay/measurement, comparison groups, independent experimental unit, exact `n`, replicate structure, summary statistic and error bars/intervals, statistical test and sidedness, multiplicity handling, exact P value where feasible, symbol/color definitions, and any scale bars; verify every legend statement against the figure and source data once supplied.
- **Journal gate:** **FAIL** — N002 technical interpretability and N006 reproducible reporting.
- **confidence:** `1.00`

## M2. Figure 3 and the Discussion mislabel data-reused splitting as independent validation

- **issue_key:** `internal-split-called-independent-validation`
- **axis:** `claim-moderation`
- **severity:** `MAJOR`
- **Anchor:** “Score construction and validation,” “Five genes were retained after stepwise selection using the entire 72-patient dataset” followed by “The same 72 patients were then randomly divided 70:30”; Figure 3 legend, “Development and validation”; Discussion, “The score was validated in an independent subset.”
- **Falsifiable concern:** Because feature selection, formula construction, cutoffs, coefficient signs, and missing-value rules used the full cohort before the split, the nominal validation subset influenced model development and is not independent. The figure and Discussion wording can mislead readers about validation status.
- **Concrete resolution test:** Either repeat the complete selection/tuning workflow within a training partition that was fixed before any validation access and evaluate once in a truly untouched cohort, preferably external, or relabel the present exercise as an internally data-reused exploratory split and remove “independent” and “validated” claims from Figure 3, Results, Discussion, Abstract, and Impact text.
- **Journal gate:** **FAIL** — N002 strength-of-evidence gate and accurate figure narrative.
- **confidence:** `1.00`

## M3. Figure 4 cannot support an anti-PD-1 sensitization claim from the stated comparison

- **issue_key:** `anti-pd1-sensitization-comparator-missing`
- **axis:** `causal-vs-correlative`
- **severity:** `MAJOR`
- **Anchor:** Mouse experiment, “All mice received anti-PD-1”; Figure 4 legend, “Cell growth and xenograft volume following EVA1 depletion”; Results, “We conclude that EVA1 inhibition sensitizes HCC to anti-PD-1.”
- **Falsifiable concern:** EVA1-depleted versus control xenografts under universal anti-PD-1 exposure can estimate a genotype-associated difference in that treatment context, but without untreated arms it cannot identify treatment sensitization or an EVA1-by-anti-PD-1 interaction.
- **Concrete resolution test:** Add a prespecified factorial comparison with control/EVA1-depleted tumours both with and without anti-PD-1, report the interaction estimate with uncertainty, and align Figure 4 and its legend to that contrast; otherwise restrict the text and display narrative to reduced xenograft volume under the tested anti-PD-1-treated condition.
- **Journal gate:** **FAIL** — N002 strength-of-evidence and causal-claim closure.
- **confidence:** `1.00`

## M4. Figure 2 association is narrated as physical T-cell exclusion and direct immune suppression

- **issue_key:** `eva1-tcell-correlation-overinterpreted`
- **axis:** `causal-vs-correlative`
- **severity:** `MAJOR`
- **Anchor:** Figure 2 legend, “Association between EVA1 expression and the T-cell score in eight tumours”; Results, “EVA1 was higher in low-infiltration tumours and correlated inversely with a T-cell score (Spearman r = −0.41, P = 0.03). We interpreted this association as evidence that EVA1 excludes T cells from HCC”; Results, “These findings show that EVA1 directly suppresses anti-tumour immunity.”
- **Falsifiable concern:** The displayed relationship is explicitly an eight-tumour association. Neither the legend nor the described assays establish spatial exclusion, directionality, or direct immune-cell suppression.
- **Concrete resolution test:** Relabel Figure 2 and related text as an association with the T-cell score, with patient-level points and uncertainty; reserve “excludes” or “directly suppresses” for experiments that directly measure immune-cell localization/function under controlled EVA1 perturbation and establish temporal/causal ordering.
- **Journal gate:** **FAIL** — N002 evidence-strength gate and the supplied causal-completeness standard.
- **confidence:** `0.99`

## M5. Quantitative result reporting omits uncertainty and analysis-defining details

- **issue_key:** `effect-estimates-uncertainty-omitted`
- **axis:** `statistical-rigor`
- **severity:** `MAJOR`
- **Anchor:** Statistical analysis, “Hazard ratios and P values were reported without confidence intervals”; Results, “hazard ratio 2.4, P = 0.04”; Results, “validation-set 3-year mortality AUC”; Mouse experiment, “Tumour volume was compared on day 21 using an unpaired t-test”; Figure 4 legend, “Cell growth and xenograft volume following EVA1 depletion.”
- **Falsifiable concern:** The precision and practical magnitude of the survival, discrimination, growth, and xenograft findings cannot be evaluated from P values and percentages alone, and the legends do not identify the uncertainty displays or analysis population.
- **Concrete resolution test:** Report effect estimates with confidence intervals for the Cox model, time-specific AUC, cell-growth contrasts, and xenograft contrasts; state denominators/events and missingness for each analysis; define the estimand and method in text and legends; ensure the plotted summaries match those values.
- **Journal gate:** **FAIL** — N002 evidence-strength and N006 interpretability/reproducibility.
- **confidence:** `1.00`

## M6. Citation placement and claim linkage are not visible in the manuscript body

- **issue_key:** `citations-not-linked-in-body`
- **axis:** `reference-support`
- **severity:** `MAJOR`
- **Anchor:** References closing text, “The Introduction cites reference 1 for the statement that no previous immune signature has clinical utility. The Discussion cites reference 2 for the claim that the five-gene score identifies patients who benefit from anti-PD-1 monotherapy”; Introduction, “none provides a universal, mechanistically validated guide to immunotherapy selection”; Discussion, “Its high AUC supports immediate use for selecting anti-PD-1 therapy.”
- **Falsifiable concern:** The body contains no visible citation markers at these claims; instead, citation assignments are described after the reference list. Thus claim-to-source linkage is not auditable in normal reading, and the supplied packet does not permit full-text semantic verification of either source.
- **Concrete resolution test:** Place citation callouts immediately after the atomic claims they support; narrow each claim to what the cited study directly establishes; complete a source-full-text support audit before submission; remove any claim lacking direct support.
- **Journal gate:** **FAIL** — N002 strength-of-evidence and N007 reference integration.
- **confidence:** `1.00` for placement failure; full semantic support remains NOT ASSESSABLE.

# MINOR issues

## m1. The Results heading itself advances a therapeutic-mechanism interpretation

- **issue_key:** `results-heading-mechanism-framing`
- **axis:** `writing-clarity`
- **severity:** `MINOR`
- **Anchor:** Results heading, “EVA1 perturbation supports a therapeutic mechanism.”
- **Falsifiable concern:** The heading presents an interpretive conclusion before the paragraph discloses that the assays were growth, PD-L1, three transcripts, and a xenograft comparison without an untreated anti-PD-1 arm.
- **Concrete resolution test:** Replace the heading with a descriptive statement of the performed assays or observed phenotypes, and reserve therapeutic-mechanism language for evidence meeting the comparator and causal tests in M3 and M4.
- **Journal gate:** **FAIL** — accurate, accessible Results narrative under N002.
- **confidence:** `0.98`

## m2. The label “3-year mortality AUC” is insufficiently defined

- **issue_key:** `time-dependent-auc-label-ambiguous`
- **axis:** `writing-clarity`
- **severity:** `MINOR`
- **Anchor:** Abstract, “area under the receiver operating characteristic curve (AUC) of 0.91 for 3-year mortality”; Results, “validation-set 3-year mortality AUC.”
- **Falsifiable concern:** The wording does not tell readers whether this is a time-dependent survival AUC, a binary ROC among patients with known 3-year status, or another estimand; these are not interchangeable under censoring.
- **Concrete resolution test:** Use one precise term throughout, define the estimator and censoring treatment in Methods, and carry the same definition into Figure 3 axes/legend and the Abstract.
- **Journal gate:** **FAIL** — N006 interpretability.
- **confidence:** `1.00`

## m3. The section title “Impact and implications” duplicates the Abstract’s unsupported deployment claims

- **issue_key:** `impact-section-duplicates-overclaim`
- **axis:** `claim-moderation`
- **severity:** `MINOR`
- **Anchor:** “Impact and implications,” “used to select anti-PD-1 therapy,” “immediately deployable biomarker,” and “a treatment strategy for all major HCC aetiologies.”
- **Falsifiable concern:** This standalone section repeats clinical-actionability and universal-aetiology claims before the manuscript has presented evidence, magnifying claims that the stated retrospective single-centre cohort and experimental comparisons cannot establish.
- **Concrete resolution test:** Remove the section or convert it to a short evidence-bounded statement that identifies the work as exploratory and omits deployment, treatment-selection, and universal-aetiology language unless independent clinical-utility evidence is added.
- **Journal gate:** **FAIL** — supplied flagship claim-ceiling standard and N002 strength-of-evidence.
- **confidence:** `0.99`

# EDITORIAL issues

## E1. Front matter and manuscript order do not match the supplied Article sequence

- **issue_key:** `nature-article-sequence-mismatch`
- **axis:** `journal-fit`
- **severity:** `EDITORIAL`
- **Anchor:** Manuscript sequence from title directly to “Synthetic benchmark manuscript,” then “Abstract,” “Impact and implications,” “Introduction,” “Patients and methods,” and later “Figure legends”; frozen profile N007, “title, authors, affiliations, summary paragraph, main text, references, tables, legends, methods, data and code availability, and required declarations.”
- **Falsifiable concern:** Authors and affiliations are not present in the supplied manuscript, “Abstract”/“Impact and implications” do not mirror the supplied summary/main-text sequence, and Methods appears before Results rather than in the profile’s stated sequence.
- **Concrete resolution test:** Assemble a submission version in the N007 order with complete front matter and required declarations; retain the synthetic-data disclaimer only if appropriate for the benchmark rather than a real submission; verify every section appears once in the final file.
- **Journal gate:** **FAIL** — N007 manuscript-order requirement.
- **confidence:** `1.00`

## E2. Figure references are not embedded at evidentiary points in the Results text

- **issue_key:** `figure-callouts-not-embedded`
- **axis:** `writing-clarity`
- **severity:** `EDITORIAL`
- **Anchor:** Results sections “Single-cell discovery identifies an immune-evasion programme,” “The five-gene score predicts survival,” and “EVA1 perturbation supports a therapeutic mechanism,” which report figure-linked findings without visible “Fig. 1,” “Fig. 2,” “Fig. 3,” or “Fig. 4” callouts.
- **Falsifiable concern:** Readers cannot move directly from each reported result to its display item, weakening figure–text traceability.
- **Concrete resolution test:** Add each figure/panel callout immediately after the sentence reporting the corresponding result and verify that every panel is cited once in logical order.
- **Journal gate:** **FAIL** — display-item navigation and accessible reporting under N002.
- **confidence:** `0.99`

# Claim-ceiling risks

- `auc-3year-three-way-conflict` and `internal-split-called-independent-validation`: the current reporting supports, at most, exploratory apparent/internal performance in one retrospective cohort; it does not support an independently validated, immediately deployable predictor.
- `anti-pd1-sensitization-comparator-missing`: the current Figure 4 narrative supports, at most, a difference between EVA1-depleted and control xenografts while both receive anti-PD-1; it does not establish sensitization, a treatment interaction, human benefit, or therapeutic readiness.
- `eva1-tcell-correlation-overinterpreted`: the current Figure 2 narrative supports an association with a T-cell score in eight tumours; it does not establish physical exclusion, direct immune suppression, or a universal mechanism.
- `impact-section-duplicates-overclaim`: no supplied figure or reporting element can close “for all major HCC aetiologies,” “universally applicable,” or “immediately deployable” from this study design.

# Required versus optional additional work

**Required for a defensible re-review under this lens**

1. Resolve the three-way AUC conflict from a versioned analysis output and make Abstract, Results, Figure 3, legend, and source table identical or explicitly estimand-specific.
2. Make the model reproducible by reporting the complete formula and depositing or providing controlled access to code, data, environment, and seeds.
3. Rewrite Figure 2 and Figure 4 narratives to match the comparisons actually described, or add the causal/interaction experiments needed for the present wording.
4. Replace each legend with a self-contained panel-level legend and report effect sizes with uncertainty.
5. Supply complete human and animal ethics declarations.
6. Correct the validation terminology, citation placement, figure callouts, front matter, and Article sequence.
7. Provide the figure images and source data for a separate visual and numerical reconciliation before any figure gate can pass.

**Optional presentation strengthening**

- Add a compact study-design schematic distinguishing discovery, model development, internal evaluation, functional perturbation, and xenograft evidence, provided it does not label data-reused evaluation as independent validation.
- Use a consistent visual vocabulary for discovery, association, prediction, and perturbation evidence across all figures.
- Add a figure-level evidence map in internal revision materials linking each central claim to its panel, analysis output, and source-data file.

# Journal-fit posture

**Current posture: major scientific and reporting rework required before Nature consideration.** Under this reporting lens alone, the package fails central figure/number, reproducibility, claim-closure, ethics, and Article-assembly gates. This report does not make the final editorial decision and does not independently assess whether the work has the novelty or broad importance required by Nature.

# NOT ASSESSABLE items

- Figure visual quality, readability, resolution, color accessibility, microscopy scale bars, panel assembly, image integrity, and whether the plotted values match the prose: figure images absent.
- Figure-to-source-data reconciliation, exact numerical recomputation, outlier handling, and whether error bars/points reflect the stated experimental unit: source data absent.
- Table content, consistency, and callouts: tables absent.
- Supplementary methods/results and reporting-checklist closure: supplementary information and checklists absent.
- Whether raw or processed data could be made available under an unstated repository or controlled-access plan: no such materials or plan supplied beyond the manuscript statement.
- Full-text semantic support by references 1 and 2: cited-paper full text was outside the frozen packet.
- Final combined-file compliance under N008: no Word/PDF file containing text and figures was supplied.

# Evidence anchors

- Abstract: “AUC of 0.91 for 3-year mortality”; “clinically actionable, universally applicable predictor.”
- Impact and implications: “used to select anti-PD-1 therapy”; “immediately deployable biomarker”; “all major HCC aetiologies.”
- Score construction and validation: full-cohort selection and rule choice before the 70:30 split; no external cohort, calibration, or decision-curve analysis.
- Results, “The five-gene score predicts survival”: AUC 0.84 in text, 0.86 in Figure 3, and incomplete 3-year status.
- Results, “Single-cell discovery identifies an immune-evasion programme”: eight-tumour correlation interpreted as exclusion.
- Mouse experiment: all mice received anti-PD-1; five per group; no blinded/random allocation or independent replication.
- Figure legends: Figures 1–4, including Figure 3 Panel C AUC 0.86.
- Data and code availability: no raw single-cell data, model code, coefficients, final patient-level dataset, seeds, or software versions.
- Ethics: missing committee/protocol, consent procedure, animal protocol, and humane endpoints.
- References closing text: citation assignments described after the reference list rather than shown at the claims.

# Confidence and reasons

Overall confidence: **0.98**. Confidence is high for textual inconsistency, legend incompleteness, reproducibility disclosure, missing ethics information, validation wording, and the stated comparison structure because these are explicit in the frozen manuscript. Confidence is deliberately withheld for visual quality and data reconciliation: those gates remain **NOT ASSESSABLE**, not failed on presumed content. The AUC values can be shown inconsistent, but which value is correct cannot be determined without the absent analysis output and source data.
